Occam Places Steve Colletti as CSO of Korro Bio
Korro Bio is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and common diseases. The company has raised over $200M across two rounds of financing. Top-tier investors include Atlas, Qiming, Fidelity, Point72, NEA, Eventide, Cormorant Asset Management, and Citadel.
In Colletti, Korro captures an RNA domain expert and a broadly gauged scientific leader who speaks the languages of both chemistry and biology, a bifocal perspective that he has leveraged to great effect across discovery and translation through early clinical development. After a highly successful R&D career at Merck, Colletti effectively transitioned to Biotech with Lodo which was subsequently acquired by Zymergen.
Recent Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.